CytomX Therapeutics Inc (CTMX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $444.73M
Last updated: Nov 17, 2026 at 4:34 PM ET
CytomX Therapeutics Inc (CTMX) Statistics
CytomX Therapeutics (CTMX) has a market cap of $444.73M and an enterprise value of $414.63M. It kept -608.98% of revenue as net income over the last 12 months. Its share count is up 32.79% from a year earlier.
Total Valuation
Enterprise value is 6.77% below the market cap, as cash exceeds debt.
| Market Cap | $444.73M |
|---|---|
| Enterprise Value | $414.63M |
| Latest price (Nov 17, 2026) | $1.94 |
Key Dates
The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 30.3x and 1.5x. Its year-end P/S ranged from 0.6x to 26.5x from 2016 to 2025.
| P/S Ratio | 30.3x |
|---|---|
| Forward P/S | 20.3x |
| P/B Ratio | 1.5x |
| P/TBV Ratio | 1.5x |
Price Statistics
The stock is down 50.00% over 52 weeks and trades 22.40% below its 50-day average.
| Beta (1Y) | 1.53 |
|---|---|
| 52-Week Change | -50.00% |
| 1-Month Change | -17.09% |
| 3-Month Change | -45.66% |
| 6-Month Change | -46.70% |
| 5-Year Change | -60.54% |
| 10-Year Change | -79.24% |
| Total Return (1Y) | -50.00% |
| Total Return (3Y CAGR) | +13.69% |
| Total Return (5Y CAGR) | -23.13% |
| Return vs SPY (1Y) | -58.55% |
| Max Drawdown (1Y) | -71.26% |
| Max Drawdown (3Y) | -91.59% |
| Sharpe Ratio (1Y) | -0.78 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $2.50 |
| 200-Day Average | $3.67 |
| 52-Week Range | $1.90 to $8.21 |
| RSI (14 Days) | 36.2 |
| Average Volume (20 Days) | 5.19M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 7.82x current liabilities, and total debt is 0.01x shareholder equity.
| Current Ratio | 7.82x |
|---|---|
| Quick Ratio | 7.82x |
| Debt / Equity | 0.01x |
Returns and Efficiency
Return on invested capital is -32.76% over the last 12 months, against a 5-year average of -22.56%.
| Return on Equity (ROE) | -29.98% |
|---|---|
| Return on Assets (ROA) | -23.42% |
| Return on Invested Capital (ROIC) | -32.76% |
| ROA (5Y Average) | -11.50% |
| ROIC (5Y Average) | -22.56% |
| Asset Turnover | 0.05x |
| Receivables Turnover | 0.74x |
Scores
CTMX has an Altman Z-Score of 0.44, in the distress zone below 1.81, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.44 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 1 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $14.03M over the last 12 months is down 87.66% from the 12 months before.
| Revenue | $14.03M |
|---|---|
| Revenue Growth (YoY) | -87.66% |
| Gross Profit | $14.03M |
| Operating Income | -$94.89M |
| Pretax Income | -$85.19M |
| Net Income | -$85.42M |
| Reported EPS (TTM) | -$0.50 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 78.12% of the $364.68M in total assets.
| Cash and Equivalents | $33.96M |
|---|---|
| Total Debt | $3.86M |
| Net Cash | $30.10M |
| Net Cash Per Share | $0.14 |
| Working Capital | $310.52M |
| Shareholder Equity | $284.89M |
| Book Value Per Share | $1.30 |
| Tangible Book Value | $283.61M |
| Tangible Book Per Share | $1.29 |
| Total Assets | $364.68M |
| Total Liabilities | $79.79M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$50.21M |
|---|---|
| FCF Per Share | -$0.23 |
| Depreciation and Amortization | $5.17M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -676.45%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -676.45% |
| Pretax Margin | -607.31% |
| Net Margin | -608.98% |
| Net Margin (5Y Average) | -99.53% |
Growth
Revenue grew 12.75% a year over 3 years.
| Revenue Growth (3Y CAGR) | +12.75% |
|---|---|
| Revenue Growth (5Y CAGR) | +2.18% |
Dividends and Yields
CTMX does not pay a dividend.
| Buyback Yield | -59.22% |
|---|---|
| Shareholder Yield | -59.22% |
Peer Position
Against 5 similar companies, CTMX has the highest P/S.
P/S RatioPeer median 1.7x
ROICPeer median -29.19%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -23.76%
| P/S Ratio | 30.3x vs 1.7x median |
|---|---|
| ROIC | -32.76% vs -29.19% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -87.66% vs -23.76% median |
Analyst Forecast
Consensus estimates put revenue growth at -41.48% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -41.48% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CTMX
What is CTMX's market cap?
CytomX Therapeutics has a market cap of $444.73M. Its enterprise value, which adds debt and subtracts cash, is $414.63M.
How many shares of CTMX are outstanding?
CytomX Therapeutics has 219.11M shares outstanding. The count is up 32.79% from a year earlier.
Does CTMX pay a dividend?
No. CytomX Therapeutics does not pay a dividend.
How much debt does CTMX have?
CytomX Therapeutics has $3.86M of total debt and $33.96M of cash and equivalents, a net cash position of $30.10M.
CTMX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors